Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells

Experimental Cell Research

Volumn 326, Issue 1, 2014, Pages 90-102

  Ristic, Biljana ^a   Bosnjak, Mihajlo ^a   Arsikin, Katarina ^a   Mircic, Aleksandar ^a   Suzin Zivkovic, Violeta ^a   Bogdanovic, Andrija ^a   Perovic, Vladimir ^a   Martinovic, Tamara ^a   Kravic Stevovic, Tamara ^a   Bumbasirevic, Vladimir ^a   Trajkovic, Vladimir ^a   Harhaji Trajkovic, Ljubica ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Apoptosis; Autophagy; Idarubicin; Leukemia; MTOR

Indexed keywords

ACRIDINE ORANGE; BAFILOMYCIN; BECLIN 1; CASPASE; CHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IDARUBICIN; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICROTUBULE ASSOCIATED LIGHT CHAIN 3B; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; WORTMANNIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL COUNT; CELL MEMBRANE DEPOLARIZATION; CELL PROTECTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC AUTOPHAGY; CYTOTOXICITY; DNA FRAGMENTATION; DOWN REGULATION; FLUORESCENCE MICROSCOPY; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; K562 CELL LINE; LIGHT CHAIN; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION;

MAMMALIA;

APOPTOSIS; AUTOPHAGY; IDARUBICIN; LEUKEMIA; MTOR;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL PROLIFERATION; HUMANS; IDARUBICIN; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84904391609     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.05.021     Document Type: Article

References (50)

1. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43:67-93.
2. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
3. Fimia G.M., Piacentini M. Toward the understanding of autophagy regulation and its interplay with cell death pathways. Cell Death Differ. 2009, 16:933-934.
4. Gozuacik D., Kimchi A. Autophagy and cell death. Curr. Top. Dev. Biol. 2007, 78:217-245.
5. White E. Autophagic cell death unraveled: pharmacological inhibition of apoptosis and autophagy enables necrosis. Autophagy 2008, 4:399-401.
6. Chaabane W., User S.D., El-Gazzah M., Jaksik R., Sajjadi E., Rzeszowska-Wolny J., Los M.J. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch. Immunol. Ther. Exp. (Warsz) 2013, 61:43-58.
7. Jia L., Dourmashkin R.R., Allen P.D., Gray A.B., Newland A.C., Kelsey S.M. Inhibition of autophagy abrogates tumour necrosis factor alpha induced apoptosis in human T-lymphoblastic leukaemic cells. Br. J. Haematol. 1997, 98:673-685.
8. Turzanski J., Daniels I., Haynes A.P. Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br. J. Haematol. 2009, 145:137-140.
9. Buckley M.M., Lamb H.M. Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Drugs Aging 1997, 11:61-86.
10. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
11. Gallois L., Fiallo M., Garnier-Suillerot A. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study. Biochim. Biophys. Acta 1998, 1370:31-40.
12. Qian H., Yang Y. Alterations of cellular organelles in human liver-derived hepatoma G2 cells induced by adriamycin. Anticancer Drugs 2009, 20:779-786.
13. Di X., Shiu R.P., Newsham I.F., Gewirtz D.A. Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to adriamycin. Biochem. Pharmacol. 2009, 77:1139-1150.
14. Lu L., Wu W., Yan J., Li X., Yu H., Yu X. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int. J. Cardiol. 2009, 134:82-90.
15. Han W., Sun J., Feng L., Wang K., Li D., Pan Q., Chen Y., Jin W., Wang X., Pan H., Jin H. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One 2011, 6:e28491.
16. Sishi B.J., Bester D.J., Wergeland A., Loos B., Jonassen A.K., van Rooyen J., Engelbrecht A.M. Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart. Exp. Biol. Med. (Maywood) 2012, 237:219-226.
17. Sun W.L., Chen J., Wang Y.P., Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 2011, 7:1035-1044.
18. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellstrom-Lindberg E., Tefferi A., Bloomfield C.D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
19. Yang T.T., Sinai P., Kain S.R. An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. Anal. Biochem. 1996, 241:103-108.
20. Kaludjerovic G.N., Miljkovic D., Momcilovic M., Djinovic V.M., Mostarica Stojkovic M., Sabo T.J., Trajkovic V. Novel platinum(IV) complexes induce rapid tumor cell death in vitro. Int. J. Cancer 2005, 116:479-486.
21. Smolewski P., Grabarek J., Phelps D.J., Darzynkiewicz Z. Stathmo-apoptosis: arresting apoptosis by fluorochrome-labeled inhibitor of caspases. Int. J. Oncol. 2001, 19:657-663.
22. Mizushima N., Yoshimori T., Levine B. Methods in mammalian autophagy research. Cell 2008, 140:313-326.
23. Sadowski-Debbing K., Coy J.F., Mier W., Hug H., Los M. Caspases-their role in apoptosis and other physiological processes as revealed by knock-out studies. Arch. Immunol. Ther. Exp. (Warsz) 2002, 50:19-34.
24. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M.E. Apoptosis signaling by death receptors. Eur. J. Biochem. 1998, 254:439-459.
25. Rubinsztein D.C., Cuervo A.M., Ravikumar B., Sarkar S., Korolchuk V., Kaushik S., Klionsky D.J. In search of an "autophagomometer". Autophagy 2009, 5:585-589.
26. Codogno P., Mehrpour M., Proikas-Cezanne T. Canonical and non-canonical autophagy: variations on a common theme of self-eating?. Nat. Rev. Mol. Cell Biol. 2012, 13:7-12.
27. Blommaart E.F., Krause U., Schellens J.P., Vreeling-Sindelarova H., Meijer A.J. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur. J. Biochem. 1997, 243:240-246.
28. Wibo M., Poole B. Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. J. Cell Biol. 1974, 63:430-440.
29. Yamamoto A., Tagawa Y., Yoshimori T., Moriyama Y., Masaki R., Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 1998, 23:33-42.
30. 4Cl of autophagy-associated proteloysis in cultured fibroblasts. Exp. Cell Res. 1978, 115:357-366.
31. Gammoh N., Lam D., Puente C., Ganley I., Marks P.A., Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc. Natl. Acad. Sci. USA 2012, 109:6561-6565.
32. 2-terminal kinase activation is essential for up-regulation of LC3 during ceramide-induced autophagy in human nasopharyngeal carcinoma cells. J. Transl. Med. 2011, 9:161.
33. Toepfer N., Childress C., Parikh A., Rukstalis D., Yang W. Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription. Cancer Biol. Ther. 2011, 12:691-699.
34. Smith D.M., Patel S., Raffoul F., Haller E., Mills G.B., Nanjundan M. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. Cell Death Differ. 2010, 17:1867-1881.
35. Tian S., Lin J., Jun Zhou J., Wang X., Li Y., Ren X., Yu W., Zhong W., Xiao J., Sheng F., Chen Y., Jin C., Li S., Zheng Z., Xia B. Beclin 1-independent autophagy induced by a Bcl-XL/Bcl-2 targeting compound, Z18. Autophagy 2010, 6:1032-1041.
36. Li J., Liu Y., Wang Z., Liu K., Wang Y., Liu J., Ding H., Yuan Z. Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. J. Virol. 2011, 85:6319-6333.
37. Park S., Chapuis N., Tamburini J., Bardet V., Cornillet-Lefebvre P., Willems L., Green A., Mayeux P., Lacombe C., Bouscary D. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010, 95:819-828.
38. Zhu W., Soonpaa M.H., Chen H., Shen W., Payne R.M., Liechty E.A., Caldwell R.L., Shou W., Field L.J. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009, 119:99-106.
39. Chen M.B., Wu X.Y., Gu J.H., Guo Q.T., Shen W.X., Lu P.H. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem. Biophys. 2011, 60:311-322.
40. Brum G., Carbone T., Still E., Correia V., Szulak K., Calianese D., Best C., Cammarata G., Higgins K., Ji F., Di W., Wan Y. N-acetylcysteine potentiates doxorubicin-induced ATM and p53 activation in ovarian cancer cells. Int. J. Oncol. 2013, 42:211-218.
41. Kaushal V., Kaushal G.P., Mehta P. Differential toxicity of anthracyclines on cultured endothelial cells. Endothelium 2004, 11:253-258.
42. Qu X., Zhang Y., Li Y., Hu X., Xu Y., Xu L., Hou K., Sada K., Liu Y. Ubiquitin ligase Cbl-b sensitizes leukemia and gastric cancer cells to anthracyclines by activating the mitochondrial pathway and modulating Akt and ERK survival signals. FEBS Lett. 2009, 583:2255-2262.
43. Lee E.R., Kim J.Y., Kang Y.J., Ahn J.Y., Kim J.H., Kim B.W., Choi H.Y., Jeong M.Y., Cho S.G. Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim. Biophys. Acta 1763, 2006:958-968.
44. Qi S.N., Yoshida A., Ueda T. Activation of caspases-3/7 is dispensable for idarubicin-induced apoptotic DNA fragmentation in human leukemia cells. Int. J. Oncol. 2003, 22:1123-1128.
45. Yu L., Wan F., Dutta S., Welsh S., Liu Z., Freundt E., Baehrecke E.H., Lenardo M. Autophagic programmed cell death by selective catalase degradation. Proc. Natl. Acad. Sci. USA 2006, 103:4952-4957.
46. Wu K.N., Zhao Y.M., He Y., Wang B.S., Du K.L., Fu S., Hu K.M., Zhang L.F., Liu L.Z., Hu Y.X., Wang Y.J., Huang H. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways. Leuk. Lymphoma 2013, 55:668-676.
47. + acute lymphoblastic leukaemia cell line. Hematol. Oncol. 2012, 30:123-130.
48. Pan Y., Gao Y., Chen L., Gao G., Dong H., Yang Y., Dong B., Chen X. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin. Cancer Res. 2011, 17:3248-3258.
49. Manov I., Pollak Y., Broneshter R., Iancu T.C. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib-the role of extracellular signal-regulated kinase counteraction. FEBS J. 2011, 278:3494-3507.
50. Sishi B.J., Loos B., van Rooyen J., Engelbrecht A.M. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem. Pharmacol. 2013, 85:124-134.